These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30177497)

  • 21. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in non-small cell lung cancer: who are the long-responders?
    Fernandes AL; Alves A; Dias M; Barroso A
    Anticancer Drugs; 2021 Nov; 32(10):1150-1152. PubMed ID: 34661552
    [No Abstract]   [Full Text] [Related]  

  • 24. Durvalumab boosts progression-free survival in NSCLC.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
    [No Abstract]   [Full Text] [Related]  

  • 25. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
    Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
    Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Hall CJ; Umeweni N; Knight H; Smith L
    Lancet Oncol; 2016 Oct; 17(10):1357-1358. PubMed ID: 27567055
    [No Abstract]   [Full Text] [Related]  

  • 27. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468
    [No Abstract]   [Full Text] [Related]  

  • 29. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
    Hellmann MD; Nabet BY; Rizvi H; Chaudhuri AA; Wells DK; Dunphy MPS; Chabon JJ; Liu CL; Hui AB; Arbour KC; Luo J; Preeshagul IR; Moding EJ; Almanza D; Bonilla RF; Sauter JL; Choi H; Tenet M; Abu-Akeel M; Plodkowski AJ; Perez Johnston R; Yoo CH; Ko RB; Stehr H; Gojenola L; Wakelee HA; Padda SK; Neal JW; Chaft JE; Kris MG; Rudin CM; Merghoub T; Li BT; Alizadeh AA; Diehn M
    Clin Cancer Res; 2020 Jun; 26(12):2849-2858. PubMed ID: 32046999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA; Bilal U; Prasad V
    Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Zhu Z; Chen P; Yan Z
    Thorac Cancer; 2018 Aug; 9(8):901-903. PubMed ID: 29932513
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
    Brower V
    Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
    [No Abstract]   [Full Text] [Related]  

  • 34. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
    Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
    Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
    [No Abstract]   [Full Text] [Related]  

  • 35. NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
    Umeweni N; Knight H; McVeigh G
    Lancet Oncol; 2016 Nov; 17(11):1483-1484. PubMed ID: 27692477
    [No Abstract]   [Full Text] [Related]  

  • 36. Atezolizumab in advanced non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Aug; 18(8):e434. PubMed ID: 28648559
    [No Abstract]   [Full Text] [Related]  

  • 37. Atezolizumab for the treatment of non-small cell lung cancer.
    Santini FC; Rudin CM
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    Zhang X; Zhang L
    JAMA Oncol; 2023 Apr; 9(4):569-570. PubMed ID: 36729440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.